Top Markets
#1 Black Phoenix Black Phoenix +354.91%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +75.96%
#4 Gold Park Gold Park +62.07%
#5 OpenEden OpenEden +51.46%
#6 Acurast Acurast +32.03%
#7 BasedHype BasedHype +27.15%
#8 Avantis Avantis +21.77%
#9 Cryptopia Cryptopia +21.54%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Canntab Therapeutics Limited Canntab Therapeutics Limited

Canntab Therapeutics Limited

PILL
Rank in Stocks #40577
Canntab Therapeutics Limited, a phytopharmaceutical firm with its main office... Canntab Therapeutics Limited, a phytopharmaceutical firm with its main office in Markham, Canada, is dedicated to the research and development of sophisticated, medical-grade cannabinoid compounds. The company's diverse portfolio within Canada includes various orally administered pharmaceutical cannabis products. These innovative dosage forms encompass extended-release cannabinoid pellets, rapid-onset cannabidiol options, multi-layered modified-release formulations, quickly dissolving flash-melt versions, and dual-layer cannabinoid tablets. Canntab's products are designed to address a wide spectrum of health concerns, such as sleep disturbances, post-traumatic stress disorder, social anxiety, different forms of addiction, arthritic conditions, general pain management, alleviating pain and stimulating appetite for cancer patients, and aiding in recovery from opioid and other painkiller dependencies.
Share Price
$0.0036163
Last synced: 2023-10-30
Market Cap
$118.21K
Change (1 day)
0.39%
Change (1 year)
0.00%
Country
CA
Trade Canntab Therapeutics Limited (PILL)

Category

Healthcare
P/E ratio for Canntab Therapeutics Limited (PILL)
P/E ratio as of 2026 TTM: 0
According to Canntab Therapeutics Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Canntab Therapeutics Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 41.61 -
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.